Premium
Use of HLA‐ and HPA ‐ Matched Platelets in Alloimmunized Patients
Author(s) -
Kekomäki R.
Publication year - 1998
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1998.tb05443.x
Subject(s) - platelet , medicine , human leukocyte antigen , immunology , antibody , platelet transfusion , refractory (planetary science) , isoantibodies , antigen , biology , astrobiology
Refractoriness for platelet transfusion is mostly due to clinical factors but may also be caused by alloimmunization. Use of leukocyte‐depleted blood cells for transfusions of patients with hematological diseases has reduced if not eliminated HLA‐alloimmunization. HLA‐antibodies reduce the survival time of incompatible platelets complicating seriously the platelet transfusion support in at least 5% of patients. If consecutive transfusions of HLA matched platelets also fail without identifiable clinical causes, HPA‐alloimmunization may have occurred. Platelets from donors phenotyped for both HLA and HPA may produce good platelet count increments and allow optimal treatment of the basic disease despite broad spectrum alloimmunization. Additional crossmatching of phenotyped platelets with patient serum may be needed to circumvent platelet‐specific antibodies of unknown specificity.